KENNETH BATE Insider Trading Transactions
Get free email notifications about insider trading for KENNETH BATE.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of KENNETH BATE. KENNETH BATE is EVP; Chief Financial Officer in MILLENNIUM PHARMACEUTICALS INC ($MLNM) and ExecVP; Head of Commercial Ops in MILLENNIUM PHARMACEUTICALS INC ($MLNM) and Director in BIOMARIN PHARMACEUTICAL INC ($BMRN) and Director in MADRIGAL PHARMACEUTICALS, INC. ($SNTA) and Director in AVEO PHARMACEUTICALS INC ($AVEO) and Director in Vanda Pharmaceuticals Inc. ($VNDA) and Director in CATABASIS PHARMACEUTICALS INC ($CATB) and Director in GENOCEA BIOSCIENCES, INC. ($GNCA) and Director in Epizyme, Inc. ($EPZM).
Latest Insider Trading Transactions of KENNETH BATE
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AVEO, BMRN, CATB, EPZM, GNCA, SNTA, MLNM, VNDA
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 02 2021 | CATB | CATABASIS PHARMACE ... | BATE KENNETH | Director | Option Exercise | A | 2.04 | 100,000 | 204,000 | 100,000 | |
Jun 30 2020 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 7.52 | 4,000 | 30,080 | 4,000 | |
Jun 19 2020 | GNCA | GENOCEA BIOSCIENCE ... | BATE KENNETH | Director | Option Exercise | A | 2.22 | 15,000 | 33,300 | 15,000 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
Jun 12 2020 | CATB | CATABASIS PHARMACE ... | BATE KENNETH | Director | Option Exercise | A | 6.17 | 7,500 | 46,275 | 7,500 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jul 19 2019 | GNCA | GENOCEA BIOSCIENCE ... | BATE KENNETH | Director | Option Exercise | A | 3.66 | 5,625 | 20,588 | 5,625 | |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 100.45 | 10,000 | 1,004,500 | 10,000 | |
Jun 13 2019 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 0.76 | 40,000 | 30,400 | 40,000 | |
Jun 07 2019 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
Jun 05 2019 | CATB | CATABASIS PHARMACE ... | BATE KENNETH | Director | Option Exercise | A | 6.53 | 7,500 | 48,975 | 7,500 | |
Jun 25 2018 | GNCA | GENOCEA BIOSCIENCE ... | BATE KENNETH | Director | Option Exercise | A | 0.99 | 45,000 | 44,550 | 45,000 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 19 2018 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 2.27 | 40,000 | 90,800 | 40,000 | |
Jun 07 2018 | CATB | CATABASIS PHARMACE ... | BATE KENNETH | Director | Option Exercise | A | 1.48 | 14,000 | 20,720 | 14,000 | |
May 31 2018 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
Jul 28 2017 | CATB | CATABASIS PHARMACE ... | BATE KENNETH | Director | Option Exercise | A | 1.27 | 6,500 | 8,255 | 6,500 | |
Jun 30 2017 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 16.46 | 10,000 | 164,600 | 10,000 | |
Jun 26 2017 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 13.65 | 12,500 | 170,625 | 12,500 | |
Jun 23 2017 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 0.70 | 57,857 | 40,500 | 57,857 | |
Jun 23 2017 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 0.70 | 20,000 | 14,000 | 20,000 | |
Jun 19 2017 | VNDA | Vanda Pharmaceutic ... | BATE KENNETH | Director | Option Exercise | A | 13.75 | 10,000 | 137,500 | 10,000 | |
Jun 19 2017 | VNDA | Vanda Pharmaceutic ... | BATE KENNETH | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Jun 15 2017 | GNCA | GENOCEA BIOSCIENCE ... | BATE KENNETH | Director | Option Exercise | A | 5.34 | 15,000 | 80,100 | 15,000 | |
Oct 24 2016 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 12.01 | 20,000 | 240,200 | 20,000 | |
Aug 05 2016 | CATB | CATABASIS PHARMACE ... | BATE KENNETH | Director | Option Exercise | A | 4.55 | 6,500 | 29,575 | 6,500 | |
Jun 09 2016 | GNCA | GENOCEA BIOSCIENCE ... | BATE KENNETH | Director | Option Exercise | A | 4.64 | 15,000 | 69,600 | 15,000 | |
May 31 2016 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 0.92 | 44,021 | 40,499 | 44,021 | |
May 31 2016 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 0.92 | 20,000 | 18,400 | 20,000 | |
May 23 2016 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 9.33 | 12,500 | 116,625 | 12,500 | |
Dec 21 2015 | VNDA | Vanda Pharmaceutic ... | BATE KENNETH | Director | Option Exercise | A | 9.38 | 35,000 | 328,300 | 35,000 | |
Jul 10 2015 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 22.78 | 7,333 | 167,046 | 7,333 | |
Jun 30 2015 | CATB | CATABASIS PHARMACE ... | BATE KENNETH | Director | Option Exercise | A | 12.21 | 11,094 | 135,458 | 11,094 | |
Jun 18 2015 | BMRN | BIOMARIN PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 122.27 | 3,300 | 403,491 | 3,300 | |
Jun 18 2015 | BMRN | BIOMARIN PHARMACEU ... | BATE KENNETH | Director | Grant | A | 0.00 | 1,100 | 0 | 11,875 | 10.8 K to 11.9 K (+10.21 %) |
Jun 01 2015 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 2.00 | 20,000 | 40,000 | 20,000 | |
Apr 06 2015 | AVEO | AVEO PHARMACEUTICA ... | BATE KENNETH | Director | Option Exercise | A | 1.61 | 25,155 | 40,500 | 25,155 | |
Mar 02 2015 | GNCA | GENOCEA BIOSCIENCE ... | BATE KENNETH | Director | Option Exercise | A | 9.08 | 5,042 | 45,781 | 5,042 | |
Sep 27 2004 | MLNM | MILLENNIUM PHARMAC ... | BATE KENNETH | ExecVP; Head of Com ... | Option Exercise | A | 13.36 | 125,000 | 1,670,000 | 125,000 | |
Sep 02 2004 | MLNM | MILLENNIUM PHARMAC ... | BATE KENNETH | ExecVP; Head of Com ... | Option Exercise | A | 12.09 | 71,250 | 861,413 | 71,250 | |
Feb 27 2004 | MLNM | MILLENNIUM PHARMAC ... | BATE KENNETH | EVP; Chief Financia ... | Option Exercise | A | 17.77 | 71,250 | 1,266,113 | 71,250 |
Page: 1